Can I stop the warfarin? A review of the risks and benefits of discontinuing anticoagulation

Journal of Palliative Medicine

Volumn 12, Issue 1, 2009, Pages 83-87

  Spiess, Jeffrey L ^a  

^a Hospice of the Western Reserve   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL DECISION MAKING; CLINICAL TRIAL; COMORBIDITY; DRUG EFFECT; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HUMAN; LIFE EXPECTANCY; PALLIATIVE THERAPY; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STROKE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; THROMBOEMBOLISM; WARFARIN;

EID: 58849129698     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2008.0164     Document Type: Review

References (32)

1. Budnitz DS, Shehab N, Kegler SR, Richards CL: Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007;147:755-765.
2. th edition). Chest 2008;133:454-545.
3. Hart RG, Pearce LA, Aguilar MI: Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-867.
4. Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation: ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2006;48:e149-246.
5. Schulman S, Rhedin A, Lindmarker P, Carlsson A, Lärfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H: A Comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995;332:1661-1665.
6. Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Lärfars G, Leijd B, Linder O, Loogna E: The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997;336:393-398.
7. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W; Warfarin Optimal Duration Italian Trial Investigators: Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001;345:165-169.
8. Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M, Imberti D, Poggio R, Ageno W, Pogliani E, Porro F, Zonzin P; Warfarin Optimal Duration Italian Trial Investigators: Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003;139:19-25.
9. Kearon C, Ginsberg JS, Anderson DR, Kovacs MJ, Wells P, Julian JA, Mackinnon B, Demers C, Douketis J, Turpie AG, Van Nguyen P, Green D, Kassis J, Kahn SR, Solymoss S, Desjardins L, Geerts W, Johnston M, Weitz JI, Hirsh J, Gent M; SOFAST Investigators: Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost 2004;2:743-749.
10. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Pattacini C, Testa S, Lensing AW, Tripodi A; PROLONG Investigators: D-Dimer Testing to Determine the Duration of Anticoagulation Therapy. N Engl J Med 2006;355:1780-1789.
11. Campbell IA, Bentley DP, Prescott RJ, Routledge PA, Shetty HGM, Williamson IJ: Anticoagulation for Three Versus Six Months in Patients with Deep Vein Thrombosis or Pulmonary Embolism, or Both: Randomised Trial. BMJ 2007;334:674-680.
12. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: Final Results. Circulation 1991;84:527-539.
13. Morocutti C, Amabile G, Fattapposta F, Nicolosi A, Matteoli S, Trappolini M, Cataldo G, Milanesi G, Lavezzari M, Pamparana F, Coccheri S.. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke 1997;28:1015-1021.
14. Gulløv AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J, Boysen G: Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998;158:1513-1521.
15. Hellemons BSP, Langenberg M, Lodder J, Vermeer F, Schouten HJ, Lemmens T, van Ree JW, Knottnerus JA: Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: Randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ 1999;319:958-964.
16. Yamaguchi T for Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group: Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: A multicenter, prospective, randomized trial. Stroke 2000;31:817-821.
17. Edvardsson N, Juul-Möller S, Ömblus R, Pehrsson K: Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. J Intern Med 2003;254:95-101.
18. Pérez-Gómez F, Alegría E, Berjón J, Iriarte JA, Zumalde J, Salvador A, Mataix L; NASPEAF Investigators: Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: A randomized multicenter study. J Am Coll Cardiol 2004;44:1557-1566.
19. Rash A, Downes T, Portner R, Yeo WW, Morgan N, Channer KS: A randomised controlled trial of Warfarin Versus Aspirin for Stroke Prevention in Octogenarians with Atrial Fibrillation (WASPO). Age and Ageing 2007;36:151-156.
20. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ; PREVENT Investigators: Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425-1434.
21. Kearon C, Ginsberg JS, Kovacs MF, Anderson DR, Wells P, Julian JA, MacKinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, Kahn SR, Kassis J, Rodger M, Hambleton J, Gent M; Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators: Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003;349:631-639.
22. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153.
23. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW; American Society of Clinical Oncology: American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490-5505.
24. Douketis JD, Johnson JA, Turpie AG: Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: Assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 2004;164:1319-1326
25. SPORTIF Executive Steering Committee for the SPORTIF V Investigators: Ximelegatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: A randomized trial. JAMA 2005;293:690-698.
26. th Edition). Chest 2008;133:234-256.
27. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-2870.
28. th Edition). Chest 2008;133:257-298.
29. Wells PS, Forgie MA, Simms M, Greene A, Touchie D, Lewis G, Anderson J, Rodger MA: The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med 2003;163:917-920.
30. Berwaerts J, Webster J: Analysis of risk factors involved in oral-anticoagulant-related intracranial hemorrhages. Q J Med 2000;93:513-521.
31. Kucher N, Connolly S, Beckman JA, Cheng LH, Tsilimingras KV, Fanikos J, Goldhaber SZ: International normalized ratio increase before warfarin-associated hemorrhage: Brief and subtle. Arch Intern Med 2004;164:2176-2179
32. th Edition). Chest 2008;133:160-198.